C FEN 0205

a randomised, double-blind, placebo-controlled study assessing the effect of fenofibrate, coenzyme Q10 and their co-administration on ventricular disatolic function in patients with type 2 diabetes

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12606000031561

Enrollment

125

Registered

2006-01-20

Start date

2003-06-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

fenofibrate 80mg + CoEnz Q10 100mg fenofibrate 80mg + CoEnz Q10 200mg fenofibrate 160mg + CoEnz Q10 100mg fenofibrate 160mg + CoEnz Q10 200mg fenofibrate 160mg CoEnz Q10 200mg 6 MONTHS INTERVENTION

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

40 Years to 79 Years

Healthy volunteers

Inclusion criteria

Type 2 diabetes patients with LVDD and LV ejection fraction equal or greater than 50%.

Exclusion criteria

Serum creatinine above 130 micromol/l, ALT/AST above 2xULN, CK above 3xULN.

Outcome results